Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > If this stock was pre split

<< Previous

Bullboard Posts

Next >>

Comment by endpntplayon Feb 10, 2021 12:21pm

181 Views

Post# 32526125

RE:RE:RE:RE:RE:RE:RE:If this stock was pre split

Man just 5X the China deal (low balling the royalties, but the point is to be conservative) and you'll see we have a ways to go before a 500M USD market cap.

Analysts have run the full DCF and the PTs reflect some of that math. 25$+

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features